Sanofi Places a €2.3 Billion Bond Issue in Three Tranches
Sanofi announced on Friday the successful placement of a €2.3 billion bond issue in three tranches, as part of its Euro Medium Term Note program. The net proceeds will be allocated to the general needs of the biopharmaceutical company.
The bond issue was structured in three tranches and placed with investors. Citigroup, HSBC, and J.P. Morgan managed the overall coordination and steering of the operation, alongside Crédit Agricole CIB, Deutsche Bank, RBC Capital Markets, and Unicredit as lead managers.
Use of Net Proceeds
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Sanofi will allocate the net proceeds from this issue to the general needs of the company, with no specific sector allocation mentioned.
Expected revenue: Le chiffre d'affaires 2026 devrait croître à un chiffre élevé à taux de change constants.
Management commentary: Pour 2026, Sanofi anticipe une croissance solide et rentable et prévoit un programme de rachat d'actions d'un montant d'un milliard d'euros en 2026; un dividende de 4,12 euros est proposé.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.